Omnicell's Q4 Earnings In Line With Expectations, Issues Mixed FY22 Guidance

Loading...
Loading...

Omnicell Inc's OMCL Q4 sales increased 25% Y/Y to $311.0 million, compared to the consensus of $311 million. 

  • The increase reflects strong demand for Omnicell's medication management adherence automation solutions and the contribution of revenues from the acquisition of RxInnovation Inc, operating as FDS Amplicare.
  • The company posted an adjusted EPS of $0.92 in line with the consensus.
  • Adjusted EBITDA was $52.0 million, compared to $51.6 million in Q4 FY20.
  • Total product bookings for FY21 increased 21% to $1.217 billion. The product backlog was $1.254 billion, an increase of 36% Y/Y.
  • The long-term portion of the product backlog was $439 million.
  • During Q4 of 2021, Omnicell acquired MarkeTouch Media, a pharmacy software solutions provider, and ReCept Holdings Inc, a specialty pharmacy management services provider. 
  • Guidance: For FY22, Omnicell expects product bookings of $1.370 billion - $1.430 billion. 
  • The company expects FY22 revenues of $1.385 billion - $1.410 billion versus the consensus of $1.3 billion.
  • Sales guidance includes product revenues of $950 million - $965 million and service revenues of $435 million - $445 million. 
  • Omnicell forecasts adjusted EBITDA of $243 million - $255 million and adjusted EPS of $3.75 - $3.95, below the consensus of $4.01.
  • For Q1 FY22, the company expects revenues of $312 million - $318 million, versus the consensus of $301.38 million.
  • The company expects Q1 FY22 adjusted EBITDA of $45 million - $49 million and adjusted EPS of $0.65 - $0.72, lower than the consensus of $0.86.
  • Price Action: OMCL shares closed lower by 4.40% at $147.60 on Monday.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...